What's Going On With Moderna Stock Wednesday?
Portfolio Pulse from Adam Eckert
Moderna, Inc (NASDAQ:MRNA) shares are trading higher after the company announced positive interim results from its Phase 1/2 trial of mRNA-1083, a combination vaccine against influenza and Covid-19. The vaccine has been selected to advance to Phase 3 trials, with regulatory approval targeted for 2025. Shares of competitor Novavax Inc (NASDAQ:NVAX) also surged after the FDA granted Emergency Use Authorization for its updated Covid-19 vaccine.
October 04, 2023 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna's stock is trading higher due to positive data from its combination vaccine trial.
Positive trial results for a company's product typically lead to an increase in stock price as it indicates potential future revenue. The advancement to Phase 3 trials also signals confidence in the product's efficacy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Novavax's stock surged after the FDA granted Emergency Use Authorization for its updated Covid-19 vaccine.
FDA approval for a company's product typically leads to an increase in stock price as it allows the product to be sold in the market, leading to potential revenue.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 50